Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Revefenacin · Yupelri, GSK-1160724

Small molecule · Antagonist of Muscarinic acetylcholine receptor M3 (CHRM3) · developed by Mylan Ireland

Approved FDA, Nov 2018
1 Registered trials

What is Revefenacin?

Revefenacin is a long-acting muscarinic antagonist that binds muscarinic receptors, with inhibition of the M3 receptor on airway smooth muscle causing bronchodilation. It is given by inhalation and is studied in COPD exacerbation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Yupelri, GSK-1160724, TD-4208, YUPELRI
Drug type
Small molecule
Targets
Muscarinic acetylcholine receptor M3 (CHRM3)
Mechanism
Antagonist of Muscarinic acetylcholine receptor M3 (CHRM3)
Pathways
Bronchoconstriction (smooth muscle contraction)
Therapy area
Respiratory
Developer
Mylan Ireland Ltd
In trials of
VTRS
FDA status
Approved as Yupelri (November 9, 2018), NDA210598 · FDA label
UNII
G2AE2VE07O

✅ FDA-approved uses

From the indications section of the FDA label (version of May 3, 2022). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07721922 Phase 4 COPD Exacerbation Not yet recruiting VTRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COPD Exacerbation

Other drugs acting on CHRM3

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.